Computational Discovery of an Allosteric Pocket on APOBEC3B and the Impact of Metal Contamination on Inhibitor Validation
Mackenzie K. Wyllie, Katherine F. M. Jones, Özlem DemiriD, Rahul Dadabhau KardileiD, Michael J. Grillo, Clare K. MorrisiD, Brandon B. Schuldt, Farzana Kabir, Sophia P. HirakisiD, Walters Michael A., Reuben S. HarrisiD, Rommie E. AmaroiD, Daniel A. HarkiiD
Abstract
The APOBEC3 (A3) family of enzymes are zinc metalloenzymes that catalyze the conversion of 2'- deoxycytidine to 2'-deoxyuridine in single stranded DNA. APOBEC3B (A3B), a member of the A3 family, has emerged as a key driver of genomic instability in many cancer types by mutating host DNA to drive tumorigenesis and therapy resistance. Small molecule inhibitors of A3B would extend the durability of current therapies by limiting mutations that promote tumor escape and therapy resistance. Consequently, a computer aided drug discovery (CADD) campaign was employed to identify inhibitors of A3B. Through molecular dynamics (MD) simulations and computational solvent mapping analysis, we identified a novel putative allosteric pocket on the c-terminal domain of A3B and virtually screened the ChemBridge Diversity Set ([~]110,000 small molecules) against both the active and predicted allosteric sites. High scoring compounds were selected for in vitro testing and triage, resulting in 13 candidate inhibitors. Using cysteine reactive probes, one of the original hit compounds was mapped to the computationally identified allosteric pocket. However, after resynthesis of representative chemotypes and further investigation using in vitro assays, none of the chemotypes retained inhibitory activity. Further analysis revealed that most of the inhibition observed in the primary assay was due to metal contamination in the screening sample, which resulted in the removal of the catalytic zinc from the enzyme active site. Although validated A3B inhibitors were not discovered in this study, we report a ligandable allosteric site on A3B and several cautionary insights for researchers developing small molecule inhibitors of zinc metalloenzymes. TOC graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=61 SRC="FIGDIR/small/591187v2_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@b7e577org.highwire.dtl.DTLVardef@13a1a43org.highwire.dtl.DTLVardef@192309eorg.highwire.dtl.DTLVardef@b60a31_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Active site plasticity and possible modes of chemical inhibition of the human DNA deaminase APOBEC3B
- Structure of the catalytically active APOBEC3G bound to a DNA oligonucleotide inhibitor reveals tetrahedral geometry of the transition state
- Structural analysis of the active site and DNA binding of human cytidine deaminase APOBEC3B
S. Hou, T. V. Silvas, … C. A. Schiffer·bioRxiv·Apr 18, 2018
- Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A
S. Harjes, H. M. Kurup, … G. B. Jameson·bioRxiv·Feb 17, 2023
- Next generation APOBEC3 inhibitors: Optimally designed for potency and nuclease stability
Adam K. Hedger, Wazo Myint, … Celia A. Schiffer·Nucleic Acids ResearchPeer-reviewed·Mar 16, 2025
- Fluorescence polarization-based fragment screen identifies inhibitors of APOBEC3A and APOBEC3B
Julianna S. Brunello, Hannah R. Allegakoen, … Jonathan M. L. Ostrem·bioRxiv·Aug 3, 2026